160 related articles for article (PubMed ID: 36512624)
21. SPOP is essential for DNA replication licensing through maintaining translation of CDT1 and CDC6 in HaCaT cells.
Sanada S; Maekawa M; Tate S; Nakaoka H; Fujisawa Y; Sayama K; Higashiyama S
Biochem Biophys Res Commun; 2023 Apr; 651():30-38. PubMed ID: 36791496
[TBL] [Abstract][Full Text] [Related]
22. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
An J; Wang C; Deng Y; Yu L; Huang H
Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
[TBL] [Abstract][Full Text] [Related]
23. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
[TBL] [Abstract][Full Text] [Related]
24. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
[TBL] [Abstract][Full Text] [Related]
25. Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer.
Guo ZQ; Zheng T; Chen B; Luo C; Ouyang S; Gong S; Li J; Mao LL; Lian F; Yang Y; Huang Y; Li L; Lu J; Zhang B; Zhou L; Ding H; Gao Z; Zhou L; Li G; Zhou R; Chen K; Liu J; Wen Y; Gong L; Ke Y; Yang SD; Qiu XB; Zhang N; Ren J; Zhong D; Yang CG; Liu J; Jiang H
Cancer Cell; 2016 Sep; 30(3):474-484. PubMed ID: 27622336
[TBL] [Abstract][Full Text] [Related]
26. Cancer Mutations of the Tumor Suppressor SPOP Disrupt the Formation of Active, Phase-Separated Compartments.
Bouchard JJ; Otero JH; Scott DC; Szulc E; Martin EW; Sabri N; Granata D; Marzahn MR; Lindorff-Larsen K; Salvatella X; Schulman BA; Mittag T
Mol Cell; 2018 Oct; 72(1):19-36.e8. PubMed ID: 30244836
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
[TBL] [Abstract][Full Text] [Related]
28. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
[TBL] [Abstract][Full Text] [Related]
29. Higher-order SPOP assembly reveals a basis for cancer mutant dysregulation.
Cuneo MJ; O'Flynn BG; Lo YH; Sabri N; Mittag T
Mol Cell; 2023 Mar; 83(5):731-745.e4. PubMed ID: 36693379
[TBL] [Abstract][Full Text] [Related]
30. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
Gao K; Shi Q; Gu Y; Yang W; He Y; Lv Z; Ding Y; Cao W; Wang C; Wan X
Cell Death Differ; 2023 Feb; 30(2):475-487. PubMed ID: 36481790
[TBL] [Abstract][Full Text] [Related]
31. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Jin X; Qing S; Li Q; Zhuang H; Shen L; Li J; Qi H; Lin T; Lin Z; Wang J; Cao X; Yang J; Ma Q; Cong L; Xi Y; Fang S; Meng X; Gong Z; Ye M; Wang S; Wang C; Gao K
Nucleic Acids Res; 2021 Jul; 49(12):6788-6803. PubMed ID: 34133717
[TBL] [Abstract][Full Text] [Related]
32. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
Wu F; Dai X; Gan W; Wan L; Li M; Mitsiades N; Wei W; Ding Q; Zhang J
Cancer Lett; 2017 Jan; 385():207-214. PubMed ID: 27780719
[TBL] [Abstract][Full Text] [Related]
34. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C
J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942
[TBL] [Abstract][Full Text] [Related]
35. Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants.
Ostertag MS; Hutwelker W; Plettenburg O; Sattler M; Popowicz GM
J Mol Biol; 2019 May; 431(11):2213-2221. PubMed ID: 31026449
[TBL] [Abstract][Full Text] [Related]
36. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.
Fong KW; Zhao JC; Song B; Zheng B; Yu J
Nat Commun; 2018 Nov; 9(1):5007. PubMed ID: 30479348
[TBL] [Abstract][Full Text] [Related]
37. SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
Bernasocchi T; Theurillat JP
Cancer Lett; 2022 Mar; 529():11-18. PubMed ID: 34974131
[TBL] [Abstract][Full Text] [Related]
38. SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors.
Dai X; Wang Z; Wei W
Cell Cycle; 2017; 16(24):2326-2329. PubMed ID: 29108467
[TBL] [Abstract][Full Text] [Related]
39. SPOP in Cancer: Phenomena, Mechanisms and Its Role in Therapeutic Implications.
Yang X; Zhu Q
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360288
[TBL] [Abstract][Full Text] [Related]
40. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
